UMG2-CD3 BTCE
/ Magna Graecia University
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 13, 2022
A NOVEL BISPECIFIC T CELL ENGAGER (UMG2-CD3) IS EFFECTIVE AGAINST CORTICAL-DERIVED ACUTE LYMPHOBLASTIC LEUKEMIA
(EHA 2022)
- "Importantly, in an in vivo immune-humanized NSG mice model,UMG2-CD3 was able to significantly inhibit tumor growth and then conferring the survival advantage of treated animals. Conclusion All our findings, demonstrated that UMG2-CD3 BTCE represents a promising immune-therapeutic agent against T-ALL to be further investigated for clinical translation."
IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD1a • CD4 • CD69 • CD8 • IFNG • IL2RA • LAMP1 • NCAM1 • TNFA
November 05, 2021
A Novel Bispecific T Cell Engager (UMG2-BTCE) Targeting CD1a-CD3ε Is Effective Against Cortical-Derived Acute Lymphoblastic Leukemia
(ASH 2021)
- "Taken together, all these results provide a framework for the clinical development of UMG2-CD3 BTCE potentially offering a novel therapeutic path for cortical-derived T-ALL."
IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD1a • CD4 • CD69 • CD8 • IFNG • IL2RA • LAMP1 • NCAM1 • TNFA
1 to 2
Of
2
Go to page
1